Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast AS's quarterly cash and cash equivalents
declined
from Dec. 2025 ($176.38 Mil) to Mar. 2026 ($165.04 Mil) but then
stayed the same
from Mar. 2026 ($165.04 Mil) to Jun. 2026 ($125.88 Mil).
Coloplast AS's annual cash and cash equivalents
declined
from Sep. 2023 ($130.37 Mil) to Sep. 2024 ($117.30 Mil) but then
increased
from Sep. 2024 ($117.30 Mil) to Sep. 2025 ($148.92 Mil).
Coloplast AS (OTCPK:CLPBY) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Coloplast AS Cash And Cash Equivalents Related Terms
Coloplast AS Cash And Cash Equivalents Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS Cash And Cash Equivalents Calculation
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
What does a Cash And Cash Equivalents of $126 Mil mean?
Coloplast AS (CLPBY) has a Cash And Cash Equivalents of $126 Mil as of Jun. 2026. Cash and cash equivalents represents the total cash and other short-term investments on hand. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Cash And Cash Equivalents too high?
Coloplast AS's current Cash And Cash Equivalents is $126 Mil. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Cash And Cash Equivalents compare to ISRG and BDX?
Coloplast AS's Cash And Cash Equivalents of $126 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash And Cash Equivalents for a Medical Devices & Instruments company?
A good Cash And Cash Equivalents depends on the Medical Devices & Instruments industry context. However, Cash And Cash Equivalents should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash And Cash Equivalents mean?
A high Cash And Cash Equivalents can signal that a stock is expensive relative to its fundamentals. Cash and cash equivalents represents the total cash and other short-term investments on hand. View historical data on Coloplast AS and its competitors. Coloplast AS's current Cash And Cash Equivalents is $126 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.44, compared to a current price of $6.95 — trading 44.1% below its estimated fair value. The current Cash And Cash Equivalents is $126 Mil. Coloplast AS's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash And Cash Equivalents calculated?
Cash And Cash Equivalents is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Cash And Cash Equivalents is $126 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.95 is trading 44.1% below its estimated GF Value™ of $12.44.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Cash And Cash Equivalents: $126 Mil
GF Value™: $12.44 vs. price of $6.95 (44.1% below fair value)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Cash And Cash Equivalents is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
